Key result
Multivessel stenting in patients with NSTE-ACS and multivessel disease was associated with a lower rate of MACE compared with culprit-vessel stenting (9.45% vs. 16.34%, P=0.02).
Why the study?
Does multivessel revascularization reduce MACE in patients with NSTE-ACS and multivessel disease compared to culprit-vessel revascularization?
Population
609 patients with non-ST elevation acute coronary syndrome (NSTE-ACS) and multivessel disease (MVD)
Comparison
Multivessel revascularization (MVR) (n=204) vs Culprit-vessel revascularization (CVR) (n=405)
Design
Cohort
Follow-up
1 year
Authors
Loading...
May support multivessel stenting in NSTE-ACS; hypothesis-generating and requires randomized confirmation before practice change.
Cohort (n=609)
Does multivessel revascularization reduce MACE in patients with NSTE-ACS and multivessel disease compared to culprit-vessel revascularization?
Odds Ratio: 0.66 (95% CI 1.12–3.47)
Absolute Event Rate: 9.45% vs 16.34%
p-value: p=0.02
Multivessel stenting in NSTE-ACS patients with multivessel disease is associated with lower 1-year MACE, primarily driven by a reduction in repeat revascularization.
Zapata et al. (2009) conducted a cohort in Non-ST elevation acute coronary syndrome (NSTE-ACS) and multivessel disease (MVD) (n=609). Multivessel revascularization (MVR) vs. Culprit-vessel revascularization (CVR) was evaluated on Composite (MACE) of death, myocardial infarction (MI), or any revascularization (OR 0.66, 95% CI 1.12-3.47, p=0.02). Multivessel stenting in patients with NSTE-ACS and multivessel disease was associated with a lower rate of MACE compared with culprit-vessel stenting (9.45% vs. 16.34%, P=0.02).